BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 19744406)

  • 21. Clinical predictors of ketamine response in treatment-resistant major depression.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Guevara S; Machado-Vieira R; Richards EM; Brutsche NE; Nolan NM; Zarate CA
    J Clin Psychiatry; 2014 May; 75(5):e417-23. PubMed ID: 24922494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
    Zarate CA; Brutsche NE; Ibrahim L; Franco-Chaves J; Diazgranados N; Cravchik A; Selter J; Marquardt CA; Liberty V; Luckenbaugh DA
    Biol Psychiatry; 2012 Jun; 71(11):939-46. PubMed ID: 22297150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.
    Gilbert JR; Yarrington JS; Wills KE; Nugent AC; Zarate CA
    Int J Neuropsychopharmacol; 2018 Aug; 21(8):740-747. PubMed ID: 29668918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.
    Nugent AC; Diazgranados N; Carlson PJ; Ibrahim L; Luckenbaugh DA; Brutsche N; Herscovitch P; Drevets WC; Zarate CA
    Bipolar Disord; 2014 Mar; 16(2):119-28. PubMed ID: 24103187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ketamine: The final frontier or another depressing end?
    Sial OK; Parise EM; Parise LF; Gnecco T; Bolaños-Guzmán CA
    Behav Brain Res; 2020 Apr; 383():112508. PubMed ID: 32017978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans.
    Zhuo C; Tian H; Li G; Chen M; Jiang D; Lin X; Xu Y; Wang W
    Brain Behav; 2019 Nov; 9(11):e01423. PubMed ID: 31617335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
    Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
    Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats.
    Hara H; Suzuki A; Kunugi A; Tajima Y; Yamada R; Kimura H
    Pharmacol Biochem Behav; 2021 Dec; 211():173289. PubMed ID: 34655652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disentangling the association of depression on the anti-fatigue effects of ketamine.
    Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA
    J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of GRIN2B , GRIA1 , and BDNF Polymorphisms on the Therapeutic Action of Ketamine and Esketamine in Treatment-Resistant Depression Patients: Secondary Analysis From a Randomized Clinical Trial.
    Beanes G; Caliman-Fontes AT; Souza-Marques B; Silva HDS; Leal GC; Carneiro BA; Guerreiro-Costa LNF; Figueiredo AV; Figueiredo CAV; Lacerda ALT; Costa RDS; Quarantini LC
    Clin Neuropharmacol; 2022 Nov-Dec 01; 45(6):151-156. PubMed ID: 36093918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous ketamine therapy in a patient with a treatment-resistant major depression.
    Liebrenz M; Borgeat A; Leisinger R; Stohler R
    Swiss Med Wkly; 2007 Apr; 137(15-16):234-6. PubMed ID: 17525879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial.
    Costi S; Soleimani L; Glasgow A; Brallier J; Spivack J; Schwartz J; Levitch CF; Richards S; Hoch M; Stade EC; Welch A; Collins KA; Feder A; Iosifescu DV; Charney DS; Murrough JW
    Neuropsychopharmacology; 2019 Sep; 44(10):1812-1819. PubMed ID: 30858518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.
    Lundin NB; Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Brutsche NE; Machado-Vieira R; Zarate CA
    Pharmacopsychiatry; 2014 Jul; 47(4-5):141-4. PubMed ID: 24955551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.
    Niciu MJ; Iadarola ND; Banerjee D; Luckenbaugh DA; Park M; Lener M; Park L; Ionescu DF; Ballard ED; Brutsche NE; Akula N; McMahon FJ; Machado-Vieira R; Nugent AC; Zarate CA
    J Psychopharmacol; 2017 Dec; 31(12):1570-1577. PubMed ID: 29039254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
    Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
    Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
    Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
    Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Ketamine for treatment of acute depression].
    Hjerrild S; Bjerre J; Pedersen RH; Videbech P
    Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.